secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2026-07-14T20:05:25+00:00
Accession:  0001628280-26-048151
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma reports preliminary Q2 2026 cash of $171.6M
--------------------------------------------------------------

- Cash and cash equivalents estimated at $171.6M as of June 30, 2026.
- Preliminary, unaudited data subject to completion of financial closing procedures.
- PricewaterhouseCoopers has not audited, reviewed, or compiled the estimate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026048151/0001628280-26-048151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026048151/cbio-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-048151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer